Who is sponsoring NCT07431437?

NCT07431437 is sponsored by Genoss Co., Ltd..

What condition does NCT07431437 study?

NCT07431437 studies PTA (Percutaneous Transluminal Angioplasty), Femoropopliteal Artery Disease.

Is NCT07431437 still recruiting?

NCT07431437 is currently enrolling by invitation. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT07431437

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

One-Year Results of GENOSS PCB Real-World Study in Femoropopliteal Artery Disease

ENROLLING BY INVITATION Last updated 24 February 2026

What this trial tests

trial in PTA (Percutaneous Transluminal Angioplasty) in 300 participants. Enrolling by invitation.

Timeline

17 June 2025

Primary endpoint
30 June 2028

30 June 2028

Quick facts

Lead sponsor	Genoss Co., Ltd.
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	300
Start date	17 June 2025
Primary completion	30 June 2028
Estimated completion	30 June 2028
Sites	1 location across South Korea

Conditions studied

PTA (Percutaneous Transluminal Angioplasty) — all drugs for PTA (Percutaneous Transluminal Angioplasty) →
Femoropopliteal Artery Disease — all drugs for Femoropopliteal Artery Disease →

Sponsor

Genoss Co., Ltd.

Who can join

Adults 19 to 85, any sex, with PTA (Percutaneous Transluminal Angioplasty) or Femoropopliteal Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB by enrolling and tracking patients who underwent percutaneous transluminal angioplasty using GENOSS PCB in patients with femoropopliteal artery disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Genoss Co., Ltd. trials

Trials by the same sponsor.

NCT07425171 — Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion · not yet recruiting
NCT07399080 — Clinical Outcomes of GENOSS PCB for Femoropopliteal Artery Disease · enrolling by invitation
NCT07159087 — The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients Wit · NA · enrolling by invitation
NCT07158307 — Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion · enrolling by invitation
NCT06168305 — Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07431437 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genoss Co., Ltd.
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07431437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing